Less may be more: how do coach developers reproduce “learner-centred” policy in practice?

Metronomic Chemotherapy: When Less May Be More

The use of low dose continuous schedules of chemotherapy (i.e. metronomic chemotherapy), delivered at lower doses by necessity compared to traditional dosing schemes, has become an increasingly popular addition to patient management in veterinary medical oncology. While the concept itself is not new, as low dose, maintenance chemotherapy protocols have been important components of treatment for...

How to do more with less?

High-Dose Antiangiogenic Therapy for Glioblastoma: Less May Be More?

John F. de Groot Author’s Affiliations: Brain Tumor Center and Department of Neuro-Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX Running Title: Dosing effects of antiangiogenic therapy in glioblastoma

High-dose antiangiogenic therapy for glioblastoma: less may be more?

Targeting angiogenesis in glioblastoma rapidly reduces vascular permeability and contrast enhancement on MRI and prolongs progression-free survival. The long-term efficacy of bevacizumab and other antiangiogenic agents is limited, however, because of the rapid development of resistance. Alternative dosing approaches may be one mechanism of prolonging therapeutic efficacy.

Ablation of Atrial Fibrillation: How Can Less Be More?